Teleflex (TFX) to Release Earnings on Thursday

Teleflex (NYSE:TFX) is projected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Teleflex to post earnings of $3.38 per share and revenue of $892.7850 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.36 by $0.37. The company had revenue of $780.90 million during the quarter, compared to analysts’ expectations of $771.53 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.42 earnings per share. On average, analysts expect Teleflex to post $14 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Teleflex Stock Performance

Shares of TFX opened at $128.26 on Thursday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41. The company has a market capitalization of $5.67 billion, a price-to-earnings ratio of 30.18, a PEG ratio of 1.82 and a beta of 1.05. The company’s 50 day simple moving average is $126.71 and its 200 day simple moving average is $123.56. Teleflex has a 1 year low of $108.90 and a 1 year high of $238.39.

Insider Buying and Selling at Teleflex

In other news, Director Andrew A. Krakauer acquired 1,000 shares of Teleflex stock in a transaction that occurred on Tuesday, August 5th. The shares were acquired at an average price of $115.25 per share, for a total transaction of $115,250.00. Following the transaction, the director directly owned 7,192 shares of the company’s stock, valued at approximately $828,878. The trade was a 16.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Liam Kelly acquired 1,500 shares of Teleflex stock in a transaction that occurred on Tuesday, August 5th. The shares were purchased at an average price of $115.07 per share, for a total transaction of $172,605.00. Following the transaction, the chief executive officer directly owned 45,267 shares in the company, valued at $5,208,873.69. The trade was a 3.43% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 5,500 shares of company stock worth $633,590 over the last three months. 1.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Teleflex

A number of institutional investors have recently made changes to their positions in TFX. State of Wyoming bought a new stake in shares of Teleflex during the 2nd quarter valued at about $111,000. EverSource Wealth Advisors LLC boosted its position in shares of Teleflex by 108.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock valued at $119,000 after purchasing an additional 521 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Teleflex by 211.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,110 shares of the medical technology company’s stock valued at $131,000 after purchasing an additional 754 shares in the last quarter. Osaic Holdings Inc. boosted its position in shares of Teleflex by 17.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,247 shares of the medical technology company’s stock valued at $148,000 after purchasing an additional 186 shares in the last quarter. Finally, Empowered Funds LLC boosted its position in shares of Teleflex by 15.8% during the 1st quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock valued at $233,000 after purchasing an additional 230 shares in the last quarter. Institutional investors own 95.62% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TFX. Wells Fargo & Company dropped their price objective on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. Royal Bank Of Canada increased their price objective on shares of Teleflex from $130.00 to $135.00 and gave the stock a “sector perform” rating in a research report on Friday, August 1st. Mizuho increased their price objective on shares of Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a research report on Friday, August 1st. Zacks Research lowered shares of Teleflex from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 30th. Finally, Wall Street Zen lowered shares of Teleflex from a “strong-buy” rating to a “buy” rating in a report on Monday, September 15th. One research analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Teleflex currently has a consensus rating of “Reduce” and a consensus target price of $141.57.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.